Hualu Biotech announced that revenue for the third quarter of 2026 was 305 million yuan, a year-on-year decrease of 17.38%; net profit losses attributable to shareholders of listed companies were 6.5544 million yuan, after deducting losses of 63.5517 million yuan in non-net profit. Revenue for the first three quarters of 2026 was 999 million yuan, up 15.12% year on year; net profit loss attributable to shareholders of listed companies was 18.9582 million yuan, after deducting loss of 18.993 million yuan in non-net profit.

Hualu Biotech announced that revenue for the third quarter of 2026 was 305 million yuan, a year-on-year decrease of 17.38%; net profit losses attributable to shareholders of listed companies were 6.5544 million yuan, after deducting losses of 63.5517 million yuan in non-net profit. Revenue for the first three quarters of 2026 was 999 million yuan, up 15.12% year on year; net profit loss attributable to shareholders of listed companies was 18.9582 million yuan, after deducting loss of 18.993 million yuan in non-net profit.